LeonardHWexlerMD

Pediatric Hematology & Oncology • Montvale, NJ

Associate Professor of Pediatrics, Columbia P&S

Overview of Dr. Wexler

Dr. Leonard Wexler is a pediatric hematologist/oncologist in Montvale, NJ and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and New York-Presbyterian Hospital. He received his medical degree from Boston University School of Medicine and has been in practice 32 years. Dr. Wexler accepts several types of health insurance, listed below. He is one of 95 doctors at Memorial Sloan Kettering Cancer Center and one of 135 doctors at New York-Presbyterian Hospital who specialize in Pediatric Hematology & Oncology. He has more than 100 publications and over 500 citings.

Office
225 Summit Avenue
Montvale, NJ 07645
Book by Phone+1(612) 284-8407

Education & Training

National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1988 - 1990
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Pediatrics, 1987 - 1988
Montefiore Medical Center/Albert Einstein College of MedicineResidency, Pediatrics, 1986 - 1987
Jacobi Medical Center/Albert Einstein College of MedicineInternship, Pediatrics, 1985 - 1986
Boston University School of MedicineClass of 1985

Certifications & Licensure

FL State Medical License 2022 - Present
NJ State Medical License 1997 - 2025
NY State Medical License 1986 - 2025
NC State Medical License 2020 - 2022
DC State Medical License 1992 - 1997
MD State Medical License 1989 - 1995
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
New York Magazine: Top Doctors Castle Connolly, 2005-2009, 2011, 2013-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Most Compassionate Doctor American Registry
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma Start of enrollment: 2003 Oct 01
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

3318 citations
Tumour exosome integrins determine organotropic metastasis
Ayuko Hoshino, Bruno Costa-Silva, Tang-Long Shen, Gonçalo Rodrigues, Ayako Hashimoto
Nature. 2015-11-19
116 citations
A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations.
Shinji Kohsaka, Neerav Shukla, Nabahet Ameur, Tatsuo Ito, Charlotte K.Y. Ng
Nature Genetics. 2014-06-01
45 citations
Insights into pediatric rhabdomyosarcoma research: Challenges and goals
Marielle E. Yohe, Christine M. Heske, Elizabeth Stewart, Peter C. Adamson, Nabil Ahmed
Pediatric Blood & Cancer. 2019-06-21

Journal Articles

MYOD1-Mutant Spindle Cell and Sclerosing Rhabdomyosarcoma: An Aggressive Subtype Irrespective of Age. A Reappraisal for Molecular Classification and Risk Stratification
Leonard H Wexler, Cristina R Antonescu, Michael P LaQuaglia, Narasimhan P Agaram, Nature

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
BCBS Alabama PPO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust POS-SE
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment